1.0806.09% ( -0.070 )
Closed: Oct 22, 16:00:00 (EDT)Current ValuationThe current P/E ratio is -0.93, within the reasonable range, cheaper than 45.59% of the time in the past 1 years, and the industry ranks 17/38, the industry Median -0.93.
-0.93xP/E
$1.08Stock price
$-1.16Earnings per share
-0.93xP/E
Stock price$1.08Earnings per share$-1.16
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -0.99x
- Typical range
- -1.49x–-0.70x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
013263952
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
HTFLUSHeartFlow | -40.72x | 74.45% | $4.82B |
SDGRUSSchrodinger | -31.11x | 16.60% | $1.69B |
CERTUSCertara | -22.50x | 2,116.80% | $1.54B |
TDOCUSTeladoc | -6.47x | 21.86% | $1.15B |
MDRXUSVeradigm | -- | -- | $834.41M |
SOPHUSSophia Genetics SA | -7.42x | 19.83% | $600.15M |
EVHUSEvolent Health | -1.08x | 84.41% | $552.86M |
CTEVUSClaritev | -1.41x | 12.62% | $398.27M |
AMWLUSAmerican Well | -3.09x | 57.74% | $241.35M |
DHUSDefinitive Healthcare | -0.93x | 28.60% | $156.43M |
HCATUSHealth Catalyst | -0.49x | 4.22% | $130.95M |
LFMDUSLifeMD | -36.00x | 195.82% | $104.60M |
RNLXYUSRENALYTIX PLC SPON ADS EACH REP 50 ORD (POST SPLIT) | -2.25x | -- | $44.68M |
DRIOUSDarioHealth | -4.77x | 62.43% | $33.40M |
ONMDUSOneMedNet | -3.45x | -- | $29.11M |
ITOCUSiTonic | -2.65x | -- | $23.63M |
AIFFUSFirefly Neuroscience | -1.70x | -- | $16.00M |
BFRGUSBullfrog AI | -1.53x | 41.27% | $9.14M |
HLYKUSHealthLynked Corp. | -1.55x | -- | $6.21M |
HCTIUSHealthcare Triangle | -0.33x | 93.28% | $5.67M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
